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Background. Pneumococcal conjugate vaccines (PCVs) are being used worldwide. A key question is whether the impact of 
PCVs on pneumonia is similar in low- and high-income populations. However, most low-income countries, where the burden of 
disease is greatest, lack reliable data that can be used to evaluate the impact. Data from middle-income countries that have both low- 
and high-income subpopulations can provide a proxy measure for the impact of the vaccine in low-income countries.
Methods. We evaluated the impact of PCV10 on hospitalizations for all-cause pneumonia in Brazil, a middle-income country 
with localities that span a broad range of human development index (HDI) levels. We used complementary time series and spatio-
temporal methods (synthetic controls and hierarchical Bayesian spatial regression) to test whether the decline in pneumonia hospi-
talizations associated with vaccine introduction varied across the socioeconomic spectrum.
Results. We found that the declines in all-cause pneumonia hospitalizations in children and young and middle-aged adults did 
not vary substantially across low and high HDI subpopulations. Moreover, the estimated declines seen in infants and young adults 
were associated with higher levels of uptake of the vaccine at a local level.
Conclusions. These results suggest that PCVs have an important impact on hospitalizations for all-cause pneumonia in both 
low- and high-income populations.
Keywords. pneumococcal conjugate vaccines; disparities; pneumonia; Brazil. 
Pneumococcal conjugate vaccines (PCVs) used in children 
have had a well-documented impact on invasive pneumococcal 
disease [1] and pneumonia [2, 3] in high- and middle-income 
countries where they have been used since 2000. More recently, 
PCVs have been introduced in many low-income countries 
around the world [4]. However, few data are available that allow 
for comparison of the impact of PCVs on pneumonia between 
low- and high-income settings.
The impact of PCVs is likely to differ between high- and 
low-income settings for many reasons. For example, differences 
in immune and nutritional status, intensity of transmission, and 
the frequency of various pneumococcal strains [5] and other res-
piratory pathogens could all lead to a greater or smaller reduc-
tion in all-cause pneumonia following the introduction of PCVs. 
Unfortunately, despite this potential for differences in the impact 
of PCVs between settings, data needed to monitor changes in 
disease rates are usually not available in low-income settings.
Data from middle-income countries, which contain relatively 
poor and affluent subpopulations, can provide a comparison of 
vaccine impact between low- and high- income populations. 
Brazil, which introduced PCV10 in 2010 using a 3 + 1 dosing 
schedule for infants (doses at 2, 4, 6, and 12  months of age) 
and a catch-up dose for children aged 12–23  months, is one 
such country. We therefore applied complementary time series 
analyses and spatiotemporal analyses to assess PCV-associated 
declines in all-cause pneumonia hospitalizations in low- and 
high-income subpopulations of Brazil.
METHODS
Hospitalization Data
In Brazil, comprehensive data are available on individuals 
who receive publicly funded healthcare; these accounted for 
approximately 82% of the national population in 2012, includ-
ing >2.5 million infants aged <12 months, although the pro-
portion covered varied locally [6]. We obtained deidentified, 
age-stratified, International Classification of Diseases, Tenth 
Revision, Clinical Modification (ICD-10), coded data on hos-
pitalizations (January 2004–December 2013) from the Unified 
Health System (SIH-SUS, Ministry of Health). “All-cause 
pneumonia” was defined as the occurrence of the ICD10 codes 
J12–J18 in a patient’s diagnosis field. Individuals with certain 
treatment packages codes (eg, post-transplant complications) 
M A J O R  A R T I C L E
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of 
America.  This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/cid/cix638
Received 25 March 2017; editorial decision 10 July 2017; accepted 20 July 2017; published 
online July 22, 2017.
Correspondence: D. M. Weinberger, PO Box 208034, New Haven, CT 06520 (Daniel.wein-
berger@yale.edu).
Clinical Infectious Diseases®  2017;65(11):1813–8
OA-CC-BY
XX
XXXX
Downloaded from https://academic.oup.com/cid/article-abstract/65/11/1813/4004801
by Kobenhavns Universitets user
on 09 May 2018
1814 • CID 2017:65 (1 December) • Warren et al
were excluded to reduce the number of cases of hospital-ac-
quired pneumonia. The control variables were defined as in 
Bruhn et al [7]. The database, data quality issues, and case defi-
nitions have been described in detail previously [6, 7].
Geographic Classifications
Brazil is divided into 5570 municipalities, 136 mesoregions 
(groupings of municipalities that are smaller than states), 27 
states, and 5 geographic regions. The 5 regions of Brazil corre-
spond roughly to different climatic conditions (defined by the 
Brazilian Institute of Geography and Statistics as north, north-
east, center-west, southeast, and south).
For the synthetic control (SC) analyses, the monthly hospital-
ization data from the municipalities were aggregated by region 
and by 3 HDI levels [8]. The development categories were based 
on the HDI for 2010 and grouped by very low/low develop-
ment (<0.60), medium development (0.60 to <0.70), or high/
very high development (≥0.70). The HDI summarizes the con-
dition of a locality based on life expectancy, education level, and 
gross national income per capita, with higher values indicating 
improved living conditions. For the spatiotemporal disease 
mapping model, all analyses were performed at the mesoregion 
and yearly aggregation levels, with each mesoregion likewise 
classified by development and by region.
Pneumococcal Conjugate Vaccine Coverage Data
The PCV coverage data were obtained from an administrative 
database (National Immunization Program) that tracks the num-
ber of first, second, third, and booster doses administered for each 
age group in each municipality and year [9]. We found that data 
quality at the municipality level was poor due to mismatches in 
the numerator (number of children vaccinated in a municipality, 
regardless of where they live) and denominator (based on number 
of children born in a municipality), which often resulted in vac-
cine uptake estimates >100%. Therefore, we aggregated the data 
to the mesoregion level. The denominator for vaccine uptake was 
defined as the number of children in the respective age band and 
was estimated from municipality-specific live-birth statistics by 
month (Sistema de Informações sobre Nascidos Vivos, Brazilian 
Ministry of Health). A cohort model (described in detail previ-
ously [10]) was used to estimate the percentage of children aged 
6–24 months who received 3+ doses of vaccine or who received 
the age-appropriate vaccine (eg, only 1 catch-up dose after age 
1 year for children not age eligible for the full series).
Time Series Analysis Using Synthetic Controls
Our statistical analyses tested whether pneumonia hospitaliza-
tions declined over time in the post-PCV10 period. To adjust 
for trends unrelated to the vaccine (eg, due to changes in health-
care delivery and use [6], changing demography, or other non-
specific health interventions), we used the SC method, with 
the same variables and prior specifications as in our previous 
analyses of national-level data from Brazil [7, 11]. The SC 
method first establishes an association between pneumonia 
and control diseases using time series data from the prevaccine 
period to create a composite, “synthetic” control. It then uses the 
behavior of the composite control time series in the post-vac-
cine period to adjust for trends unrelated to the vaccine. The 
2 major assumptions are that the vaccine does not influence 
the control time series and that the association between pneu-
monia and the control time series is consistent over time and 
is only influenced by the vaccine. The models were fit to the 
pre-PCV10 data (2004–2009) and used to generate a counter-
factual estimate of the number of pneumonia hospitalization 
cases that would have occurred without vaccine introduction 
for the period 2012–2013. The rate ratios (RRs) were calculated 
by comparing the total number of observed cases and coun-
terfactual cases for 2012–2013. The analysis was performed 
separately for national-level data and for data disaggregated by 
region or by HDI level. In sensitivity analyses, the top 1, 2, or 
3 weighted variables were excluded, and the models were refit.
Mesoregion-Level Spatiotemporal Model
We evaluated the association between pneumonia hospitaliza-
tions and uptake of PCV10 using a varying coefficient Poisson 
regression model that explicitly models spatial relationships 
among mesoregions [12, 13]. The outcome was the number of 
hospitalizations for all-cause pneumonia in a given year and 
mesoregion. The main predictor of interest was the uptake of 
PCV10 among children aged 6–23 months in that same year 
and mesoregion. We also included nonrespiratory hospitaliza-
tions as a covariate to adjust for variations in the volume of 
hospitalizations and population size, and we included other 
specific disease categories identified in the SC analysis as con-
trol variables (see Supplementary Materials). The model was 
structured to minimize confounding the effects of the vaccine 
with secular time trends, to control for unrelated spatially and 
temporally varying confounders, and to share information 
between related geographic areas and development levels dur-
ing estimation of the parameters. For details on the model, see 
the Supplementary Materials.
As a check on the results, we also fit a standard negative bino-
mial regression model where the outcome was hospitalization 
for pneumonia per year in a mesoregion and the covariates were 
nonrespiratory hospitalizations in that year and mesoregion 
(log scale), a dummy variable for year, a dummy variable for 
region, and vaccine uptake in the mesoregion and year.
The RR specific to each mesoregion and year was estimated 
by multiplying the estimated mesoregion-specific regression 
slope by the vaccine uptake for that mesoregion in a given 
year and exponentiating this quantity. This RR describes the 
expected change in all-cause pneumonia hospitalization counts 
when going from no vaccine to the level of uptake in the given 
year. Marginal mean estimates for the entire population and for 
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each HDI group and region were calculated as described in the 
Supplementary Materials.
Inference for the spatiotemporal model was carried out in the 
Bayesian setting using the R-INLA (integrated nested Laplace 
approximation) package in the R statistical software program 
[14–16]. All parameters were assigned weak, minimally inform-
ative prior distributions (see Supplementary Materials).
Spatiotemporal Model Sensitivity Analysis
In a sensitivity analysis, we randomly swapped the vaccine 
uptake time series among mesoregions within a region and 
reran the spatiotemporal statistical model to estimate the vac-
cine effects of interest. If the association between vaccine uptake 
and pneumonia is not confounded, estimates of the RR from 
models with swapped data should be centered around 1 (ie, no 
association). However, if vaccine uptake is actually confounded 
with a variable that is not currently included in our model, we 
would expect similar vaccine effect estimates as in the true 
(unswapped) analyses. Results that are similar between the 2 
analyses for a particular age group suggest that the observed 
results may be due to confounding and should be interpreted 
with caution. To compare the estimates from the model with 
the observed or swapped data, we subtracted the swapped vac-
cine effect estimate from the true vaccine effect estimate for 
each mesoregion, exponentiated to convert to the RR scale, and 
plotted them as in the main analysis. For more details on the 
sensitivity analysis, see the Supplementary Materials.
RESULTS
Characteristics of the Databases
During the study period (2004–2013), hospital discharge data 
for Brazil included >2.9 million hospitalizations with a discharge 
code of “pneumonia” (J12–J18) among children aged <5 years 
living in 136 mesoregions (5570 municipalities) throughout 
the country. PCV10 was introduced in 2010. Uptake was high 
by the end of our study period (median uptake of 86% among 
children aged 6–23 months nationally in December 2013) but 
varied considerably by mesoregion, ranging from 50% to 97% 
(Supplementary Figures S1 and S2). A broad range of HDI val-
ues was represented among the municipalities, ranging from 
“very low” to “very high” development, although relatively 
few municipalities fell into the development categories at the 
extremes (Supplementary Figures S1 and S2).
Changes in All-Cause Pneumonia Hospitalizations Do Not Vary by 
Development Level (Time Series)
First, we evaluated overall changes in the occurrence of pneu-
monia following the introduction of PCV10 in 2010 using 
the SC method (Figure 1, Supplementary Figures S2 and S3). 
Hospitalizations for all-cause pneumonia declined by 25.5% 
(95% credible interval [CI], 18.1%, 31.6%) nationally among 
children aged <12  months. When we further stratified the 
<12 month age group, we found a decline of 22% among infants 
aged <3 months (95% CI, 12%, 29%) and 23% (95% CI, 17%, 
29%) among infants aged 3–11 months. Similar declines were 
estimated for older children and young adults, while no declines 
were detected using national data for adults aged 40–64, 65–79, 
or ≥80 years (Figure 1, Supplementary Figure S3).
The declines that occurred in children and young adults fol-
lowing the introduction of PCV10 were comparable in localities 
that were categorized as high/very high, medium, and very low/
low development (Figure 1). In adults aged 40–64 years, declines 
in pneumonia were only detected in areas classified as very low/
low development. No decline in all-cause pneumonia hospitali-
zations was detected in adults aged 65–79 and ≥80 years for any 
level of development (Figure 1). We performed sensitivity anal-
yses in which the most heavily weighted control variables were 
dropped from the SC model and found that the results did not 
change appreciably (Supplementary Table S1). We also evaluated 
a simple model that adjusted only for seasonality and the volume 
of nonrespiratory hospitalization (Supplementary Figure S4).
Changes in All-Cause Pneumonia Hospitalizations by Development Level 
(Spatiotemporal Analysis)
In a complementary analysis, we used a spatiotemporal model 
to determine whether changes in all-cause pneumonia hospi-
talizations across the 136 mesoregions in Brazil were associated 
with variations in the uptake of PCV10. We found that higher 
uptake of PCV10 in a mesoregion was associated with fewer hos-
pitalizations for pneumonia among children aged <12 months 
(marginal mean RR, 0.83; 95% CI, 0.72, 0.96) and among adults 
aged 18–39 years (marginal mean RR, 0.81; 95% CI, 0.70, 0.93). 
The marginal mean represents the estimated decline for each age 
group associated with increasing vaccine coverage from zero to 
the national median uptake among infants in 2013 (86%), while 
controlling for development levels and region. The strength 
of this association did not vary significantly among very low/
low-, medium-, and high/very high-development mesore-
gions (Figure  2). When we further stratified the youngest age 
group, we detected a significant association among children 
aged <3 months (as in the SC analysis). We did not detect an 
association between variations in uptake of PCV10 and pneu-
monia for children aged 3–11  months or for any of the other 
age groups (overall marginal mean RR estimates did not differ 
significantly from 1). The age pattern of estimates from a more 
standard regression model was similar to that of the spatiotem-
poral model—significant negative association in infants aged 
<12  months and those aged 18–39  year, a significant positive 
association in those aged ≥80 year (not seen in the spatiotempo-
ral model), and no association for other age groups.
Vaccine Impact Does Not Vary Appreciably by Mesoregion and Region
Estimates from the SC model (Figure 1B) and the spatiotem-
poral model (Supplementary Figure S5) suggested that there 
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were variations in vaccine impact by mesoregion and region 
that could not be explained by variations in vaccine coverage. 
To explore potential biases that could influence the subnational 
estimates, we performed a sensitivity analysis for the spatio-
temporal model in which we used vaccine uptake time series 
that had been randomly swapped among mesoregions within 
the same region. If the associations in the original model were 
confounded by a time-varying regional factor, we would expect 
that the swapped time series would show similar associations. 
Importantly, for children aged <12  months and young adults 
aged 18–39  years, the swapped results showed that the over-
all association between PCV10 and pneumonia was not con-
founded (Figure 2B). However, much of the variability between 
mesoregions could, in fact, be attributed to confounding. 
Notably, the apparent increase in cases associated with the vac-
cine in the older age groups was likely due to confounding, as 
was much of the variability between mesoregions in the other 
age groups (Figure 2B).
DISCUSSION
The impact of PCVs on pneumonia hospitalizations in high-in-
come settings has been well established [2]. However, few 
data are available on the population-level impact of PCVs on 
pneumonia in low-income countries [17–19]. Using subna-
tional data from Brazil, we demonstrated that declines in the 
occurrence of hospitalizations for pneumonia in children and 
young to middle-aged adults following the introduction of 
PCV10 were consistent across regions classified as very-low/
low, medium, and high/very-high development. This supports 
the notion that PCVs should reduce pneumonia hospitalization 
in both high- and low-income populations. While the low-in-
come regions of Brazil are not a perfect proxy for low-income 
populations in other regions, the living conditions might be 
similar to those seen elsewhere (eg, large urban slums and iso-
lated rural populations). Because the incidence of pneumonia 
and other pneumococcal diseases is so much greater in low-in-
come countries than in high-income countries [20], even a 
modest benefit of the vaccine would translate into a large num-
ber of hospitalizations prevented.
The 2 complementary approaches that we used to evaluate 
the impact of PCV10 on hospitalizations for pneumonia yielded 
different estimates for certain age groups (eg, children aged 
3–11 month). The time series analysis (SC method) measures 
the overall decline in pneumonia hospitalizations that occurs 
following vaccine introduction, while the spatiotemporal anal-
ysis assesses whether variability in pneumonia hospitalizations 
between localities can be attributed to higher uptake of PCV10. 
Figure 1. Change in pneumonia hospitalizations following the introduction of the 10-valent pneumococcal conjugate vaccine in Brazil as estimated with the synthetic 
control model, comparing the observed and predicted number of cases in 2012–2013 by age group and human development index level (A) and by age group and region (B). 
Median +/–95% credible intervals. Abbreviations: N, north; NE, northeast; C, center-west; SE, southeast; S, south.
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Because the 2 approaches measure different quantities, it is not 
surprising that they would yield different estimates. In particular, 
the spatiotemporal model controls for overall temporal declines 
in pneumonia common to all mesoregions using a dummy var-
iable for year. As a result, the model effectively quantifies only 
the residual variation between mesoregions. Therefore, the lack 
of a significant effect in some age groups with the spatiotem-
poral model does not mean that PCV10 failed to reduce pneu-
monia hospitalizations in these age groups. Instead, it suggests 
that there simply is not a linear association over time between 
uptake of PCV10 and all-cause pneumonia hospitalizations at 
the mesoregion level and/or that there is not enough variability 
in uptake across time between the mesoregions to estimate a 
significant difference. Noise in the mesoregion-level data (eg, 
due to changes in child welfare programs) could potentially 
obscure a true association, as could inaccuracies in the vaccine 
uptake data. Additionally, vaccine uptake among children aged 
6–23  months might not be the measure of vaccine coverage 
most relevant to the other age groups, and the effects might 
be nonlinear. Finally, if the indirect effect relies on a particular 
threshold of uptake being reached, then there might not be a 
clear dose–response linear relationship as the model assumes.
The analyses presented here have several notable strengths. 
We used a large database of hospitalizations for pneumonia 
and applied 2 complementary statistical approaches to estimate 
changes associated with PCV10 introduction. The SC approach 
is a robust method for reducing the influence of unmeasured 
confounding on estimates of vaccine impact [7, 11], and the 
spatiotemporal model leverages variations in vaccine uptake 
between mesoregions to estimate vaccine-associated changes. 
We performed sensitivity analyses for both of these analyses 
that confirmed our findings.
Figure 2. A, Rate ratio (RR) by mesoregion, with bubbles colored by human development index (HDI) level. The size of the bubble is proportional to the number of cases of pneu-
monia in that age group and mesoregion in 2013. B, Ratio of the RRs calculated using the observed coverage data and the median of the RRs calculated using swapped coverage 
estimates. A ratio of 1 indicates that there was no true effect of the vaccine. Colors denote HDI level: green = very low/low, orange = medium, purple = high/very high.
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This study also has several important limitations. We relied 
on a nonspecific definition (all-cause pneumonia) drawn from a 
large administrative database. As we have previously reported [6], 
these types of administrative data can be subject to a number of 
important quality issues that can influence the interpretation of the 
analyses. The SC approach is designed to minimize biases in these 
data, but it is impossible to eliminate their influence. In addition, 
the database we used only captures public healthcare. This covers 
approximately 80% of the population nationally, but coverage of 
the system varies by region and over time. Finally, we did not have 
a way of auditing the quality of the data. In particular, the defini-
tion of “all-cause pneumonia” might vary. This would be an issue if 
the specificity changes (eg, fraction that are X-ray confirmed) over 
time or between regions. Likewise, we did not have a way to audit 
the hospitalization [21] or vaccine uptake data on the national level 
or to evaluate timeliness of vaccination, something that can be 
done in certain localities using record linkages [22].
In conclusion, we have demonstrated that declines in all-
cause pneumonia associated with the introduction of PCV10 
are consistent across a broad range of development levels. This 
suggests that the vaccine could have a significant impact in 
low-income populations.
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